Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Commercials—How Are They Still a Thing?

Philip Seo, MD, MHS  |  Issue: July 2018  |  July 19, 2018

As for its impact on the patient, the question becomes, “Where do First Amendment rights give way to the patient’s right not to be misled?” The Supreme Court has consistently held that freedom of speech is not an absolute right. Justice Oliver Wendell Holmes famously held that “the most stringent protection of free speech would not protect a man falsely shouting fire in a theater and causing panic.”10

Where Do We Go from Here?

The Responsibility in Drug Advertising Act seems like a reasonable compromise and a reasonable start. DTC advertising is not going anywhere—its roots are too deeply entwined in American jurisprudence to be extirpated—but that does not mean we should not be willing to study the issue, to try to figure out how to strike a balance between reality and the images of happy people playing catch or walking down a beach.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Philip Seo, MD, MHSPhilip Seo, MD, MHS, is an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore. He is director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program.

References

  1. The impact of direct-to-consumer advertising. U.S. Food & Drug Administration. 2015 Oct 23.
  2. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA. 2015 Apr 27;293(16):1995–2002.
  3. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007 Aug 16;357(7):673–681.
  4. H.R. 4565 (114th Congress): Responsibility in Drug Advertising Act of 2016. GovTrack.
  5. Direct-to-consumer advertising under fire. Bulletin of the World Health Organization. 2009 Aug;87(8):565–644.
  6. Gershon L. Should drug makers advertise? JStor Daily. 2018 Mar 8.
  7. Va. Pharmacy Bd. V. Va. Consumer Council. 425 U.S. 748 (1976).
  8. Virginia State Board of Pharmacy v. Virginia Citizens Consumer Council, Inc. Oyez.
  9. Phillips-Fein K. Company men. The New Republic. 2018 Mar 29.
  10. Schenck v. United States. 249 U.S. 47 (1917).

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient management

Related Articles

    Advertise This

    March 18, 2011

    Medical marketing is an interesting place; beware inaccurate claims

    Pharma awaits FDA Guidance to Navigate the Murky Waters of Ads Via the Internet and Social Media

    November 1, 2010

    There’s no question that direct-to-consumer (DTC) advertising of prescription drugs is a huge activity, with nearly $5 billion spent on DTC ads in 2007. There’s also no question that the Internet has a vast potential to reach consumers. But when you put DTC advertising and the Internet together, there is a potential for problems and…

    U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers

    November 19, 2015

    (Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…

    The Impact of U.S. Supreme Court Decisions on Medical Affairs, Healthcare Policy

    October 11, 2016

    As America’s capital, Washington, D.C., maintains an outsized influence in our daily lives. Despite having a meager sliver of the New York City population, the daily political transactions that transpire in the District of Columbia impact our lives. The comings and goings in the corridors of Congress are likely to have a greater impact on us…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences